|
Showing 1 - 1 of
1 matches in All Departments
Therapeutic options for patients with myeloma have dramatically
changed over the past 10 years. Beginning with the advances in
therapy resulting from the use of high-dose therapy and autologous
bone marrow or stem cell tra- plant, we have more than doubled the
median survival for patients as a whole, and have now have a wealth
of different biology -based treatment approaches for our patients
in all disease stages. This book represents state-of-the-art
information from many of the leaders in the plasma cell disorders
world. Sections focusing on disease pathogenesis and biology,
chemotherapy-based approaches, immune -based therapies, currently
approved novel agents, developing targets, supportive care, and
other plasma cell disorders provides a comprehensive collection and
an excellent resource in this time of rapid change in clinical and
preclinical disease knowledge. It is important to realize that
these changes did not occur in a vacuum. Partnerships between
academic institutions, the pharmaceutical industry, patient
advocacy groups, the National Cancer Institute, community onco-
gists, and ultimately our patients worked closely together to
realize these advances, and to effect the radical changes in
therapy we have witnessed over the past few years. This book would
not have been possible without contri- tions from each of the
gifted scientists and clinicians who worked tirelessly to prepare
their individual chapters all the while maintaining commitment to
the scientific and clinical mission of advancing care.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.